Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

SAN FRANCISCO, CA—Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors. The risk of disease progression or death was 79% lower for patients treated with the experimental drug compared with patients who received octreotide LAR 60 mg every 4 weeks. These findings were presented at the 2016 Gastrointestinal Cancers Symposium.

177Lutetium-DOTATATE is a member of a new class of drugs known as peptide receptor radionuclide therapy (PRRT), a combination of hormone therapy and radiotherapy. This particular drug has a somatostatin analog attached to a radioactive molecule that allows targeted delivery of radiation to kill cancer tumors.

Midgut neuroendocrine tumors begin in the small intestine and proximal colon. The typical treatment is hormone therapy with a somatostatin analog, such as octreotide or lanreotide. Currently, no effective systemic second-line treatment options exist for patients whose tumors stop responding to somatostatin analogs.

In this study, designed to evaluate the efficacy of 177Lutetium-DOTATATE in patients with advanced midgut neuroendocrine tumors, the 230 patients enrolled had advanced tumors that worsened despite first-line somatostatin analog therapy. Participants were randomly assigned to treatment with 177Lutetium-DOTATATE or high-dose octreotide LAR. The trial included 15 sites in the United States and 36 in Europe.

“Our results indicate that Lutathera appears to be a safe and effective treatment option. On average, tumors responded to the drug for several years before they began growing again,” said Jonathan R. Strosberg, MD, a medical oncologist at the Moffitt Cancer Center in Tampa, Florida, and lead author of the study. “The new therapy is also more convenient. It requires only 4 treatments, as opposed to medications that patients have to take daily over long periods of time.”

Trial enrollment was completed in February 2015. Preliminary findings suggest that 177Lutetium-DOTATATE may extend patients survival. The median progression-free survival was not yet reached for 177Lutetium-DOTATATE; it was 8.4 months for high-dose octreotide LAR.

The data was too early to analyze overall survival. Initial results suggest that 177Lutetium-DOTATATE may extend patient survival, as substantially fewer deaths occurred in the 177Lutetium-DOTATATE group vs the high-dose octreotide LAR group (13 vs 22).

The number of responses, including both complete and partial responses, was 19 (18.8%) in the 177Lutetium-DOTATATE group and 3 (3.0%) in the high-dose octreotide LAR group.

Both treatment groups had similar rates of adverse events and serious adverse events. 177Lutetium-DOTATATE can cause low blood cell counts that are typically transient.

This study received funding from Advanced Accelerator Applications (AAA), a radiopharmaceutical company that specializes in molecular nuclear medicine.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs